NASDAQ · HOWL
Werewolf Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for HOWL: Nov 3, 2026
Werewolf Therapeutics, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-0.36.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews- Zacks · Oct 16, 10:21 AM EDTRoche Gets FDA Approval for Enspryng in Thyroid Eye DiseaseRHHBY wins FDA approval for Enspryng in thyroid eye disease, offering the first and only at-home subcutaneous treatment option for patients.
- Zacks · Oct 16, 10:19 AM EDTKRYS Reports Positive Early Data for KB113 in Gorlin SyndromeKrystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.
- Zacks · Oct 13, 11:00 AM EDTWerewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's WhyWerewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Oct 13, 9:47 AM EDTTGTX Stock Rises 60% in 6 Months: Here's What You Should KnowTG Therapeutics shares climb 59.9% in six months on strong Briumvi sales uptake, higher 2026 revenue guidance and studies targeting additional indications.
- Zacks · Oct 13, 9:41 AM EDTMirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver DiseasesMIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
- Zacks · Oct 9, 5:46 AM EDTNew Strong Buy Stocks for October 9thLITE, HOWL, PERI, GSBD and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 9th, 2026.
- Zacks · Oct 7, 9:58 AM EDTHALO Expands ENHANZE Collaboration & Licensing Deal With ARGXHalozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.
- RTTNews · Aug 21, 8:41 AM EDTWerewolf Therapeutics And Ambros Therapeutics Announce Merger; Secure $150M Financing(RTTNews) – Shares of Werewolf Therapeutics, Inc. (HOWL) are up 1431.19% in pre-market trading after the company announced a definitive all-stock merger agreement with Ambros Therapeutics.
- RTTNews · Aug 21, 8:33 AM EDTWerewolf Therapeutics, Ambros Therapeutics To Combine In All-stock Deal(RTTNews) – Werewolf Therapeutics (HOWL) and Ambros Therapeutics have entered into a definitive merger agreement to combine in an all-stock deal. The combined company will focus on advancing Ambros Therapeutics neridronate development program in Complex Regional Pain Syndrome Typ
- RTTNews · Aug 20, 10:38 PM EDTAfter-hours Gainers: HOWL Jumps 90%, MODD To Begin Pivot Pump Rollout, BIVI Awaits Long COVID Data(RTTNews) – The SPDR S&P Biotech ETF (XBI), a broad benchmark for the U.S. biotech sector, fell 3.64% during regular trading Thursday but edged 0.21% higher in after-hours trading. Among the notable biotech gainers in after-hours trading were Werewolf Therapeutics, which is advan
- Zacks · Aug 4, 1:42 PM EDTJAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 ViewJazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
- RTTNews · Jul 31, 11:21 AM EDTWerewolf Turns Q2 Profit On Revenue From Jazz Collaboration; Cash Runway Extended Through Q2 2027(RTTNews) – Werewolf Therapeutics (HOWL) on Friday reported a net profit for the second quarter ended June 30, 2026, driven by significant gains from a collaboration revenue. Company Profile Werewolf Therapeutics is a clinical-stage biopharmaceutical company focused on develo
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Werewolf Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.